Dennis M. Lanfear - 04 Jan 2024 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role: President & CEO, Director
Signature: /s/ Bryan McMichael, as Attorney-in-Fact for Dennis M. Lanfear
Issuer symbol: CHRS
Transactions as of: 04 Jan 2024
Net transactions value: -$34,401
Form type: 4
Filing time: 08 Jan 2024, 19:04:08 UTC
Previous filing: 24 Nov 2023
Next filing: 23 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CHRS	Common Stock	Tax liability	$34,401	-11,781	-1.6%	$2.92	719,912	04 Jan 2024	Direct	F1
holding	CHRS	Common Stock						432,684	04 Jan 2024	By Trust	F2
holding	CHRS	Common Stock						86,965	04 Jan 2024	By LLC	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CHRS	Stock Option (Right to Buy)	Award	$0	+575,000		$0.000000	575,000	05 Jan 2024	Common Stock	575,000	$3.14	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares automatically withheld to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3.
F2	These shares are held by the Lanfear Revocable Trust, dated January 27, 2004, as restated, of which Reporting Person is a trustee.
F3	These shares are held by Lanfear Capital Advisors, LLC of which Reporting Person is President.
F4	1/48th of the total number of shares subject to the option shall vest in successive, equal monthly installments measured from January 5, 2024, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.